Chronic Hepatitis B

Jacobson, Ira M.

doi:10.1016/j.cld.2023.06.001

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…63 While there are suppressive therapies for HBV, they are not curative and do not decrease the risk of HCC. 64 HBV can be transmitted via the allograft 65,66 or acquired post-transplant via bodily fluids (including semen, vaginal discharge, blood, and saliva), sexual contact, and sharing of needles or syringes. 67 The risk for donor-derived transplant-associated HBV may be higher in areas with high rates of intravenous drug use in the donor population.…”

Section: Hepatitis B Virus and Hepatocellular Carcinomamentioning

confidence: 99%

Adult and late adolescent complications of pediatric solid organ transplantation

Byeman,

Harshman,

Engen

2024

Pediatric Transplantation

View full text Add to dashboard Cite

BackgroundThere have been over 51 000 pediatric solid organ transplants since 1988 in the United States alone, leading to a growing population of long‐term survivors who face complications of childhood organ failure and long‐term immunosuppression.AimsThis is an educational review of existing literature.ResultsPediatric solid organ transplant recipients are at increased risk for risk for cardiovascular and kidney disease, skin cancers, and growth problems, though the severity of impact may vary by organ type. Pediatric recipients often are able to complete schooling, maintain a job, and form family and social networks in adulthood, though at somewhat lower rates than the general population, but face additional challenges related to neurocognitive deficits, mental health disorders, and discrimination.ConclusionsTransplant centers and research programs should expand their focus to include long‐term well‐being. Increased collaboration between pediatric and adult transplant specialists will be necessary to better understand and manage long‐term complications.

show abstract

Section: Hepatitis B Virus and Hepatocellular Carcinomamentioning

confidence: 99%

Adult and late adolescent complications of pediatric solid organ transplantation

Byeman,

Harshman,

Engen

2024

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

Chen

2024

J of Gastro and Hepatol

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) was, and still is, a prevalent liver disease in the world, especially high in the Asia‐Pacific areas. With the advent of preventive vaccines and effective viral suppression drugs and active implementations, CHB has gradually become under control. The world‐wide prevalence reduces from 4.2% in 1980 to 3.2% in 2020 study. CHB patients receiving long‐term antiviral therapies significantly improve the clinical outcomes, saving from end‐stage liver diseases. Despite of these impressive progresses, to meet the WHO sustained development goals (SDG) for CHB control, a 90% reduction of incidence and a 65% reduction of mortality in year 2030, there is still a long way to go. In this review, four ongoing approaches have been proposed: (i) A continuous monitoring of long‐term vaccine efficacy in vaccinated populations; (ii) consolidating the hepatitis B virus vaccination program against vaccine hesitancy and limited resources; (iii) rolling‐out current oral antivirals to more CHB patients not only for diseases treatment but also for infection preventions; and (iv) development of curative therapies, both friendly‐to‐dispense and affordable. A coherent and persevere efforts by the society may succeed and achieve the SDG for CHB in the future.

show abstract

Chronic Hepatitis B

Cited by 2 publications

References 63 publications

Adult and late adolescent complications of pediatric solid organ transplantation

Adult and late adolescent complications of pediatric solid organ transplantation

Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

Contact Info

Product

Resources

About